SCHEMBL23218283

SCHEMBL23218283

CCOC(=O)Cc1ccccc1OCc1coc2c(CN3C[C@@H](C)O[C@@H](C)C3)cc(Br)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 5/20 0.36
TBXAS1 P24557 1/20 0.36
HTT P42858 3/20 0.36
CCR5 P51681 1/20 0.36
KMT2A Q03164 4/20 0.35
GAA P10253 2/20 0.35
PKM P14618 1/20 0.35
TSHR P16473 2/20 0.34
POLB P06746 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
NPC1 O15118 1/20 0.34
BLM P54132 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CFD P00746 1/20 0.34
MEN1 O00255 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852851 1.00 KDM4E (0.36) KDM4EALDH1A1TBXAS1HTTCCR5
SCHEMBL23218351 0.88 CCR5 (0.39) KDM4EALDH1A1TBXAS1HTTCCR5
SCHEMBL29852448 0.88 CCR5 (0.39) KDM4EALDH1A1TBXAS1HTTCCR5
SCHEMBL29852449 0.87 CCR5 (0.40) KDM4EALDH1A1TBXAS1CCR5KMT2A
SCHEMBL23229202 0.87 CCR5 (0.40) KDM4EALDH1A1TBXAS1CCR5KMT2A
SCHEMBL23218445 0.87 CCR5 (0.40) KDM4EALDH1A1TBXAS1HTTCCR5
SCHEMBL23219084 0.87 KDM4E (0.39) KDM4EALDH1A1TBXAS1HTTCCR5
SCHEMBL28736146 0.85 KDM4E (0.39) KDM4EALDH1A1TBXAS1HTTCCR5
SCHEMBL23218227 0.85 CCR5 (0.37) KDM4EALDH1A1TBXAS1HTTCCR5
SCHEMBL23218828 0.84 CFD (0.47) KDM4EALDH1A1HTTPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB KDM4E 4172/4885ALDH1A1 2667/4885TBXAS1 963/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB KDM4E 4491/4885ALDH1A1 3142/4885TBXAS1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.